Gene expression profiles to predict relapse of prostate cancer
The present disclosure provides a method for cancer relapse prediction that provides higher resolution grading than Gleason score alone. In particular, the method provides for prediction of prostate cancer relapse that correlates gene expression of each individual signature gene and deriving a prostate cancer gene expression (GEX) score in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1.
1. A method for predicting the probability of relapse of prostate cancer in an individual, said method comprising the steps of
(a) providing a prostate tissue sample for a test individual,
(b) providing expression levels for a collection of signature genes from said sample, wherein said collection of signature genes comprises CCK and at least one of GI — 2094528, MKI67, MEMD, FBP1, and CDC6,
(c) determining a gene expression analogy of the Gleason score for said collection of signature genes by deriving a Gene Expression score that captures said expression levels for said collection of signature genes,
(d) providing a reference model comprising information correlating said Gene Expression score with prostate cancer relapse, and
(e) comparing said Gene Expression score to said reference model thereby determining the probability of prostate cancer relapse for said individual.
2. The method of claim 1 , wherein said individual has a Gleason score between seven and eight.
3. The method of claim 2 , wherein said Gleason score is based on a primary grade of four.
4. The method of claim 2 , wherein said Gleason score is based on a primary grade of three.
5. The method of claim 1 , further comprising providing a report having a prediction of prostate cancer relapse for said individual.
6. The method of claim 1 , wherein said collection of signature genes further comprises HOXC6, KIP2, NRG1, NBL1, Prostein, CCNE2, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, AZGP1, MLCK, PPAP2B, and PROK1.
7. The method of claim 1 , wherein said collection of signature genes further comprises at least one of HOXC6, CCNE2, MYBL2, PTTG1, RAMP, UBEC2C, Wnt5A, AZGP1, MLCK, PPAP2B, and PROK1.
8. The method of claim 1 , wherein said collection of signature genes further comprises at least two of HOXC6, CCNE2, MYBL2, PTTG1, RAMP, UBEC2C, Wnt5A, AZGP1, MLCK, PPAP2B, and PROK1.
9. The method of claim 1 , wherein said score is a better predictor of prostate cancer relapse than a Gleason score.
10. The method of claim 1 , wherein said collection further comprises at least one gene selected from the group consisting of HOXC6, CCNE2, MYBL2, PTTG1, RAMP, UBEC2C, Wnt5A, AZGP1, MLCK, PPAP2B, and PROK1.